Tilray Brands, Inc. (TLRY) Stock Analysis and Metrics

Tilray Brands

NASDAQ: TLRY

$3.88 ▼ -0.11 (-2.63%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap439.44 Mn

P/E-0.30

P/S0.51

Div. Yield0.00

ROIC (Qtr)-0.08

Total Debt (Qtr)143.82 Mn

Revenue Growth (1y) (Qtr)11.28

Add ratio to table…

About

Tilray Brands, Inc. is a leading global lifestyle consumer products company that operates at the intersection of cannabis beverage wellness and entertainment. The company develops manufactures markets and sells a diverse portfolio of brands that span alcoholic beverages nonalcoholic drinks craft spirits medical and adult use cannabis products and hemp based foods. Its activities are supported by production facilities in the United States Canada Europe and Latin America and by a distribution network that reaches customers in over 20 countries. Tilray Brands aims to build brand equity and consumer loyalty through high quality products that create memorable experiences.

The company generates revenue primarily from the sale of cannabis beverages and wellness products. In fiscal year 2025 the beverage segment contributed 29 percent of total net revenue the cannabis segment 30 percent the distribution segment 33 percent and the wellness segment 8 percent. Cannabis revenue comes from medical and adult use flower pre rolls vapes topicals edibles and beverages sold in Canada and internationally. Beverage revenue is derived from craft beer spirits and nonalcoholic drinks sold through retail outlets bars restaurants and other venues across the United States and abroad. Wellness revenue stems from hemp based foods proteins seeds and functional beverages sold to retailers wholesalers and direct consumers. Distribution revenue arises from the purchase resale and logistics of pharmaceutical and wellness products including medical cannabis supplied to pharmacies and hospitals in Germany and other markets.

The company operates through the following segments: Beverage Cannabis Distribution Wellness.

• Beverage: This segment produces markets and sells craft beer craft spirits and nonalcoholic beverages under a portfolio of brands such as SweetWater Montauk Shock Top 10 Barrel Breckenridge Blue Point and others and operates production facilities in the United States that supply distributors retailers bars restaurants airports sports venues and airlines including Delta Air Lines.

• Cannabis: This segment cultivates produces distributes and sells medical and adult use cannabis products including flower pre rolls vapes topicals edibles and beverages through facilities in Canada Portugal and Germany and supplies patients in more than 20 countries worldwide.

• Distribution: This segment purchases resells and distributes pharmaceutical and wellness products including medical cannabis through its German subsidiary CC Pharma which supplies public pharmacies hospital pharmacies specialized pharmacies and pharmaceutical wholesalers in Europe and other markets.

• Wellness: This segment produces markets and distributes hemp based foods proteins seeds and functional beverages under brands such as Manitoba Harvest Hemp Yeah Just Hemp Foods and The Humble Seed and sells them through more than 21,000 retail locations in the United States and Canada and in eighteen countries worldwide.

Tilray Brands holds a strong position in each of its markets. In the United States it is ranked as the fourth largest craft brewer according to the Brewers Association. In Canada it generates the highest cannabis revenue among licensed producers and maintains a leading share of the medical and adult use markets. Internationally the company supplies medical cannabis to patients in over twenty countries and operates EU GMP certified facilities in Portugal and Germany. Its distribution arm CC Pharma is one of the leading drug importers in Germany while its wellness division is a top provider of hemp based foods in North America. Competitors include other craft brewers cannabis producers pharmaceutical distributors and hemp food specialists but Tilray Brands differentiates itself through a diversified brand portfolio integrated production and distribution capabilities and a focus on innovation and cost efficiency.

The company serves a broad range of customers including retail consumers hospitality venues and institutional buyers. Its beverage brands are available in nearly fifty thousand off premises retail locations more than thirty thousand restaurants and bars and in venues such as Delta Air Lines flights John F Kennedy International Airport Long Island MacArthur Airport Hartsfield Jackson Atlanta International Airport Denver International Airport and stadiums of the New York Mets Denver Nuggets Atlanta United University of Florida Portland Timbers University of Colorado University of Denver University of Oregon and University of Washington. The distribution segment supplies public pharmacies hospital pharmacies specialized pharmacies and pharmaceutical wholesalers in Germany and other European markets. The wellness segment reaches consumers through grocery stores natural food retailers and direct to consumer channels in the United States Canada and eighteen additional countries.

Investment Thesis

▲ Bull case

The fundamental reclassification of cannabis from Schedule 1 to Schedule 3 represents a profound structural shift that the market is significantly underestimating in terms of its impact on the research and development capabilities of TLRY. By moving into a category with a low to moderate potential for abuse, the legal and administrative obstacles that previously hindered large scale clinical trials are being dismantled. This transition allows the company to pivot from a traditional producer of consumable goods toward a highly specialized biotechnology model that focuses on pharmaceutical grade cannabinoid based medicines. The ability to conduct rigorous and multi year studies will facilitate the creation of standardized products for complex medical conditions such as endometriosis or chronic inflammatory diseases. Investors are currently valuing the company based on its legacy commodity assets while ignoring the massive margin expansion that will occur as it captures the high value medical pharmaceutical market. This evolution from a simple grower to a sophisticated drug developer is a catalyst that the market has not yet priced into the valuation.
The reduction in federal regulatory risk serves as a powerful and overlooked catalyst for the revitalization of the banking and financial ecosystem for the entire industry. For many years, the primary inhibitor of growth has been the inability of cannabis companies to access traditional banking, credit unions, and sophisticated payment processing services due to the fear of federal prosecution. As the Department of Justice accelerates the rescheduling process, the perceived risk for financial institutions will diminish, encouraging a much broader range of banks to provide essential services like checking accounts, escrow, and commercial lending. This increased access to institutional capital will allow for much more efficient debt management and provide the necessary liquidity for large scale capital expenditures and acquisitions. The market is currently overlooking the profound impact that a more integrated and mainstream financial environment will have on the ability of the company to execute its long term growth strategy. The influx of capital from more conservative institutions will significantly lower the cost of capital and improve the overall solvency and expansion potential of the firm.
The shift toward a more regulated and standardized industry landscape is a critical driver for the long term sustainability and global scalability of the company. The move toward Schedule 3 status encourages much higher standards for product quality, consistency, and safety, which is a prerequisite for gaining the trust of the broader healthcare community. As cannabis products become more standardized, they can be integrated into the modern healthcare paradigm alongside other legitimate pharmaceutical therapies. This professionalization of the industry will allow for easier entry into new markets and the development of more reliable and data driven treatment protocols. The market is failing to recognize that this standardization is the key to unlocking the massive addressable market of patients and healthcare providers who require high quality and regulated products. This structural move toward legitimacy is a permanent shift that will redefine the valuation metrics of the entire sector.

The fundamental reclassification of cannabis from Schedule 1 to Schedule 3 represents a profound structural shift that the market is significantly underestimating in terms of its impact on the research and development capabilities of TLRY. By moving into a category with a low to moderate potential for abuse, the legal and administrative obstacles that previously hindered large scale clinical trials are being dismantled. This transition allows the company to pivot from a traditional producer of consumable goods toward a highly specialized biotechnology model that focuses on pharmaceutical grade cannabinoid based medicines. The ability to conduct rigorous and multi year studies will facilitate the creation of standardized products for complex medical conditions such as endometriosis or chronic inflammatory diseases. Investors are currently valuing the company based on its legacy commodity assets while ignoring the massive margin expansion that will occur as it captures the high value medical pharmaceutical market. This evolution from a simple grower to a sophisticated drug developer is a catalyst that the market has not yet priced into the valuation.
The reduction in federal regulatory risk serves as a powerful and overlooked catalyst for the revitalization of the banking and financial ecosystem for the entire industry. For many years, the primary inhibitor of growth has been the inability of cannabis companies to access traditional banking, credit unions, and sophisticated payment processing services due to the fear of federal prosecution. As the Department of Justice accelerates the rescheduling process, the perceived risk for financial institutions will diminish, encouraging a much broader range of banks to provide essential services like checking accounts, escrow, and commercial lending. This increased access to institutional capital will allow for much more efficient debt management and provide the necessary liquidity for large scale capital expenditures and acquisitions. The market is currently overlooking the profound impact that a more integrated and mainstream financial environment will have on the ability of the company to execute its long term growth strategy. The influx of capital from more conservative institutions will significantly lower the cost of capital and improve the overall solvency and expansion potential of the firm.
The shift toward a more regulated and standardized industry landscape is a critical driver for the long term sustainability and global scalability of the company. The move toward Schedule 3 status encourages much higher standards for product quality, consistency, and safety, which is a prerequisite for gaining the trust of the broader healthcare community. As cannabis products become more standardized, they can be integrated into the modern healthcare paradigm alongside other legitimate pharmaceutical therapies. This professionalization of the industry will allow for easier entry into new markets and the development of more reliable and data driven treatment protocols. The market is failing to recognize that this standardization is the key to unlocking the massive addressable market of patients and healthcare providers who require high quality and regulated products. This structural move toward legitimacy is a permanent shift that will redefine the valuation metrics of the entire sector.

▼ Bear case

Despite the positive momentum of the rescheduling process, the market is ignoring the reality that for TLRY, this is merely a partial measure that fails to address the fundamental legal void regarding adult use cannabis. The current Department of Justice action does not extend to the legalization of recreational cannabis at the federal level, which means the largest and most lucrative segment of the potential market remains in a state of legal uncertainty. This creates a highly fragmented and confusing regulatory landscape where companies must navigate a complex patchwork of conflicting state and federal laws. Without a full federal reform that includes the absolute legalization of adult use, the industry will continue to face significant regulatory and political headwinds. The market is being far too optimistic about the transformative power of rescheduling while ignoring the massive regulatory ceiling that exists because the federal government has not addressed the adult use market. This persistent legal ambiguity will continue to act as a significant drag on the total addressable market and the ability of the company to achieve full scale domestic dominance.
A critical operational risk that is being overlooked by investors is the persistent and unresolved difficulty within the financial and payment infrastructure of the cannabis industry. Even with the progression toward Schedule 3, the fundamental challenges of how cannabis businesses accept electronic payments and manage their cash flow without disruption remain largely unaddressed. The industry's continued reliance on cash heavy operations increases the risk of theft, administrative errors, and significant compliance costs. Furthermore, the transition of the banking sector is unlikely to happen overnight, as many financial institutions will remain cautious until the entire rescheduling process is finalized and becomes legally unassailable. This lack of robust and technology enabled payment solutions creates a persistent drag on the margins of the entire supply chain, including the upstream producers. Investors are failing to recognize that the structural inefficiency of the payment ecosystem will continue to be a major headwind for the foreseeable future and could impact the overall profitability of the company.
The significant timeline risk associated with the administrative and legal implementation of the rescheduling process is a major hurdle that could lead to prolonged periods of corporate stagnation. The rescheduling process is not an instantaneous event but is instead a complex and protracted administrative procedure that involves public hearings, intense lobbying, and potential litigation from various stakeholders. This period of transition could drag on for several years, during which time the industry will remain in a state of extreme uncertainty and limited clarity. The market is currently pricing in a smooth and rapid transition, but the potential for significant legal challenges and bureaucratic delays is substantial. During this period of regulatory flux, the costs associated with navigating the changing landscape could erode the very benefits that the rescheduling was intended to provide. The market is ignoring the risk that the entire process could become mired in litigation, leaving the industry in a state of transition for an extended period.
The broader socio-political challenges regarding criminalization and the long term consequences of cannabis related arrests continue to pose a systemic risk to the industry. The current rescheduling efforts do not address the significant legal and social issues surrounding the lifelong restrictions faced by individuals with previous cannabis related offenses. This ongoing criminalization creates a landscape of social instability and political volatility that can lead to sudden and unpredictable shifts in the regulatory and legislative environment. As long as the underlying issues of cannabis related prosecution and the legal status of non violent offenders remain unresolved, the industry will be subject to the whims of political administrations. The market is overlooking the fact that the cannabis sector remains a highly politicized and volatile asset class that is vulnerable to changes in the executive branch and legislative priorities. This volatility introduces a layer of risk that is not yet fully reflected in the current market pricing.

Despite the positive momentum of the rescheduling process, the market is ignoring the reality that for TLRY, this is merely a partial measure that fails to address the fundamental legal void regarding adult use cannabis. The current Department of Justice action does not extend to the legalization of recreational cannabis at the federal level, which means the largest and most lucrative segment of the potential market remains in a state of legal uncertainty. This creates a highly fragmented and confusing regulatory landscape where companies must navigate a complex patchwork of conflicting state and federal laws. Without a full federal reform that includes the absolute legalization of adult use, the industry will continue to face significant regulatory and political headwinds. The market is being far too optimistic about the transformative power of rescheduling while ignoring the massive regulatory ceiling that exists because the federal government has not addressed the adult use market. This persistent legal ambiguity will continue to act as a significant drag on the total addressable market and the ability of the company to achieve full scale domestic dominance.
A critical operational risk that is being overlooked by investors is the persistent and unresolved difficulty within the financial and payment infrastructure of the cannabis industry. Even with the progression toward Schedule 3, the fundamental challenges of how cannabis businesses accept electronic payments and manage their cash flow without disruption remain largely unaddressed. The industry's continued reliance on cash heavy operations increases the risk of theft, administrative errors, and significant compliance costs. Furthermore, the transition of the banking sector is unlikely to happen overnight, as many financial institutions will remain cautious until the entire rescheduling process is finalized and becomes legally unassailable. This lack of robust and technology enabled payment solutions creates a persistent drag on the margins of the entire supply chain, including the upstream producers. Investors are failing to recognize that the structural inefficiency of the payment ecosystem will continue to be a major headwind for the foreseeable future and could impact the overall profitability of the company.
The significant timeline risk associated with the administrative and legal implementation of the rescheduling process is a major hurdle that could lead to prolonged periods of corporate stagnation. The rescheduling process is not an instantaneous event but is instead a complex and protracted administrative procedure that involves public hearings, intense lobbying, and potential litigation from various stakeholders. This period of transition could drag on for several years, during which time the industry will remain in a state of extreme uncertainty and limited clarity. The market is currently pricing in a smooth and rapid transition, but the potential for significant legal challenges and bureaucratic delays is substantial. During this period of regulatory flux, the costs associated with navigating the changing landscape could erode the very benefits that the rescheduling was intended to provide. The market is ignoring the risk that the entire process could become mired in litigation, leaving the industry in a state of transition for an extended period.
The broader socio-political challenges regarding criminalization and the long term consequences of cannabis related arrests continue to pose a systemic risk to the industry. The current rescheduling efforts do not address the significant legal and social issues surrounding the lifelong restrictions faced by individuals with previous cannabis related offenses. This ongoing criminalization creates a landscape of social instability and political volatility that can lead to sudden and unpredictable shifts in the regulatory and legislative environment. As long as the underlying issues of cannabis related prosecution and the legal status of non violent offenders remain unresolved, the industry will be subject to the whims of political administrations. The market is overlooking the fact that the cannabis sector remains a highly politicized and volatile asset class that is vulnerable to changes in the executive branch and legislative priorities. This volatility introduces a layer of risk that is not yet fully reflected in the current market pricing.

Ownership Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Consolidated Entities Breakdown of Revenue (2025)

Ownership Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Consolidated Entities Breakdown of Revenue (2025)

Ownership Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password